logo

For the Inventor, By the Inventor

La Jolla, CA, United States of America

Inhibrx, Inc.


USPTO Granted Patents = 30



Trademarks = 3

Forward Citations = 141

Loading Chart...
Loading Chart...

23 inventors (with patents filed for the assignee):

goldMedal John C Timmer (30 out of 41 patents)

silverMedal Brendan P Eckelman (30 out of 44 patents)

bronzeMedal Quinn L Deveraux (24 out of 38 patents)

4.  Kyle S Jones (14 out of 15 patents)

5.  Amir S Razai (10 out of 12 patents)

6.  Peter L Nguy (9 out of 9 patents)

7.  Abrahim Hussain (8 out of 10 patents)

8.  Katelyn M Willis (7 out of 12 patents)

9.  Grant B Guenther (7 out of 7 patents)

10.  Rajay A Pandit (5 out of 10 patents)

11.  Andrew Hollands (5 out of 6 patents)

12.  Bryan Becklund (4 out of 5 patents)

13.  William Crago (4 out of 7 patents)

14.  Angelica N Sanabria (3 out of 8 patents)

15.  Florian Sulzmaier (3 out of 4 patents)


30 patents:

1. 12012459 - OX40-binding polypeptides and uses thereof (2024-06-18),
2. 11976126 - Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells (2024-05-07),
3. 11965017 - Serpin fusion polypeptides and methods of use thereof (2024-04-23),
4. 11945869 - PD-1 single domain antibodies and therapeutic compositions thereof (2024-04-02),
5. 11919963 - CD123-binding polypeptides and uses thereof (2024-03-05),
6. 11866507 - Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same (2024-01-09),
7. 11827691 - Serpin fusion polypeptides and methods of use thereof (2023-11-28),
8. 11566078 - PDL1-binding proteins (2023-01-31),
9. 11560428 - CD33-binding polypeptides and uses thereof (2023-01-24),
10. 11434297 - CD123-binding polypeptides and uses thereof (2022-09-06),
11. 11208485 - PD-1 single domain antibodies and therapeutic compositions thereof (2021-12-28),
12. 11117973 - Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms (2021-09-14),
13. 11117972 - Multivalent and multispecific OX40-binding fusion proteins (2021-09-14),
14. 11046752 - Serpin fusion polypeptides and methods of use thereof (2021-06-29),
15. 10844129 - Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids (2020-11-24),
InhibRx, Inc. is a biotechnology company that specializes in the development and commercialization of innovative antibody-based therapeutics for the treatment of cancer and other diseases. Their mission is to improve patient outcomes and quality of life through the discovery and delivery of breakthrough therapies. With a focus on antibody engineering and development, InhibRx aims to create highly effective and targeted treatments that address unmet medical needs. Through their cutting-edge research and development programs, InhibRx strives to revolutionize the field of cancer treatment and make a positive impact on global health.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

...
30 Patents

#23 in La Jolla, CA

#2,592 in California

#10,852 in US

#21,227 in the World

...
La Jolla, CA, United States of America

Inhibrx, Inc.

Forward Citations = 141

23 inventors:

goldMedal John C Timmer (30 out of 41 patents)

silverMedal Brendan P Eckelman (30 out of 44 patents)

bronzeMedal Quinn L Deveraux (24 out of 38 patents)

4.  Kyle S Jones (14 out of 15 patents)

5.  Amir S Razai (10 out of 12 patents)

Please report any incorrect information to support@idiyas.com
Loading…